Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
19,080
Total Claims
$7.9M
Drug Cost
1,611
Beneficiaries
$4,912
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+25%
Cost per patient vs peers
$4,912 vs $3,933 avg
-4%
Brand preference vs peers
49.0% vs 51.2% avg
Brand vs Generic
Brand: 8,272 claims · $7.5M
Generic: 8,597 claims · $316K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 1,192 | $1.1M |
| Insulin Aspart | 518 | $583K |
| Semaglutide | 428 | $566K |
| Dapagliflozin Propanediol | 581 | $474K |
| Insulin Aspart Prot/Insuln Asp | 397 | $450K |
| Sitagliptin Phosphate | 481 | $417K |
| Semaglutide | 272 | $376K |
| Insulin Lispro Protamin/Lispro | 253 | $305K |
| Linagliptin | 337 | $276K |
| Dulaglutide | 178 | $244K |
| Insulin Lispro | 223 | $222K |
| Insulin Glargine,hum.Rec.Anlog | 349 | $209K |
| Insulin Lispro Protamin/Lispro | 208 | $187K |
| Sitagliptin Phos/Metformin Hcl | 202 | $177K |
| Insulin Degludec | 112 | $172K |
Prescribing Profile
Patient Profile
74
Avg Age
58%
Female
1.69
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data